Videos
Brand-name drugs versus generic treatment options
Multiple myeloma expert Dr. Brian G.M. Durie discusses if patients should consider switching from brand-name drugs to available generic options.
The BOTTOM LINE: Talk to your doctor to see if there is any benefit…
Event
My name is George, and I lost my dad and a brother to multiple myeloma. My wife, Julia's best friend, is on her 11th year fighting this dreadful disease. So, this year as Julia and I celebrate our 50th anniversary, we decided to help by collaborating with the International Myeloma…
Page
国际骨髓瘤基金会 (IMF) 成立于 1990 年，是第一个也是最大的专注于多发性骨髓瘤的组织。基金组织的影响力扩展到全球 140 个国家的 525,000 多名成员。 IMF 致力于提高骨髓瘤患者的生活质量，同时通过我们的四项创始原则：研究、教育、支持和宣传，致力于预防和治疗。
国际货币基金组织为患者和护理人员以及医疗保健专业人员制作并维护着一个包含最新教育出版物和期刊的广泛图书馆。基金组织的所有出版物始终免费，可通过单击下面的链接下载。
出版物…
News Article
LOS ANGELES, CA, MAY 12, 2022—The International Myeloma Foundation (IMF) announced today that Fatima Scipione, former Head of Global Oncology Patient Advocacy and Engagement at Takeda Oncology, has been named by the nonprofit research and patient advocacy organization as its new…
News Article
Members of the myeloma community fund important myeloma research
By Suzanne Battaglia
IMF Senior Director, Member Events
Since 1994, the IMF has funded more than 150 of the most promising myeloma research projects by talented investigators from leading institutions around the world. The IMF’…
News Article
YOU can help the IMF collect and study important data to ensure that the right patient gets the right treatment at the right time!
By Lynn K. Green, Ed.D.
IMF Senior Vice President, Philanthropy
Patients have always been the primary focus of the IMF’s mission: to improve the quality of life…
News Article
5th Annual AMN Summit, Inaugural Master Class for Doctors, and Patient Forum
By Daniel Navid
IMF Senior Vice President, Global Affairs
The IMF Asian Myeloma Network held three groundbreaking events for the region, which took place on consecutive weekends in October 2021.…
News Article
Patients must have access to oral cancer therapies
By Robin Levy
IMF Senior Director, Public Policy & Advocacy
Improving access to lifesaving medications for myeloma patients is a long-standing commitment of the International Myeloma Foundation (IMF).
For many years, the IMF Advocacy…
Audio
You're listening to A Day in The Life podcast brought to you by the International Myeloma Foundation. We hope this podcast provides messages of hope and resilience for those in the myeloma community and beyond.
Today, we are talking to Thomas Goode, who was diagnosed with myeloma in 2005, at the…
Event
In 2007, I was diagnosed with multiple myeloma. At that time, there was only a few drugs approved and those were very taxing on you. Revlimid had just been approved so I started with Revlimid, velcade and dexamethazone (RVD). RVD worked great at first, but within 6 months the myeloma came…
Videos
What is the IMF's virtual tissue bank?
Myeloma expert Dr. Brian G.M. Durie discusses the virtual biobank being developed by the International Myeloma Working Group (IMWG).
The BOTTOM LINE: The virtual tissue bank is a major development that will enhance collaborative research…
News Article
STUDIO CITY, CA, April 6, 2022 — As this year’s Myeloma Action Month came to a close, the International Myeloma Foundation (IMF) was unwavering in achieving its goals. By encouraging individuals and groups to take action for myeloma through a powerful social media campaign, the IMF…
Audio
This "A Day in the Life" podcast provides messages of hope and resilience to those in the myeloma community and beyond. In this episode we're talking to Marisel Brignoni from San Juan, Puerto Rico. Marisel is a FEMA disaster relief specialist who's working on the disaster relief for Hurricane…
Page
The Role of Oncology Nurses and Advanced Practitioners in Advancing Health Equity in the Field of Multiple Myeloma
The following videos, presented by Medscape Oncology, are designed for healthcare practitioners to earn certified medical education (CME) credits.
In this CME series, …
Page
Understanding the Language of Multiple Myeloma
Myeloma is a complicated disease, but the language that describes myeloma doesn’t have to be hard to understand. To play an active role in your own medical care, it is helpful to learn the myeloma-related terms that may be used in your discussions…
Event
Single Malt Scottish Whisky Tasting Tour in the comfort of your own home or venue of your choosing.
Videos
What Patients and Caregivers Need to Know About Side Effect Management and Living Well with Myeloma
DOWNLOAD SLIDES
Speakers
Agenda…
Page
Our hearts go to all innocent victims of the ongoing conflict in Ukraine.
As a global organization, the International Myeloma Foundation supports — and will continue to support — every myeloma patient, caregiver, doctor, researcher, and advocate going through struggles and difficulties…
Page
What Is Carvykti?CARVYKTI® (also known as ciltacabtagene autoleucel, the generic drug name, or “cilta-cel” for short). Carvykti was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). …
News Article
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of…
Event
A virtual multiple myeloma workshop addressing the needs specific to communities in the Northeast Tri-State of the United States.
Register Now
News Article
STUDIO CITY, Calif., Feb. 25, 2022 — With the International Myeloma Foundation (IMF) at the forefront, Myeloma Action Month is held every year for the whole month of March to encourage individuals and groups to take actions that positively impact the …
Videos
Paxlovid Has Been Granted Emergency Use Authorization To Treat the COVID-19 Infection.
Myeloma Expert Dr. Brian G.M. Durie answers the question: How does Pfizer’s antiviral pill used to treat COVID-19 infections benefit myeloma patients?
The BOTTOM LINE: Paxlovid™…
Videos
Dr. Stephen Harding discusses the continued partnership with the Binding Site and Dr. Sigurdur Kristinsson at the University of Iceland. Dr. Kristinsson leads the iStopMM study, and the Binding Site have analyzed more than 75,000 samples from study participants. The recent results from the…
Videos
Background:
Cancer screening is performed worldwide for several malignancies. Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM) and related lymphoproliferative disorders (LP). However, less than 5% of all MM patients are…
Videos
CAR T Therapy Is an Innovative and Groundbreaking Approach to Myeloma Treatment
What is CAR T therapy and how can it benefit myeloma patients?
In this video, IMF Chairman of The Board Dr. Brian G.M. Durie and IMF Chief Medical Officer Joseph Mikhael, MD, along with other myeloma experts,…
Page
For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of more than 30,000 health-care professionals from around the world. Explore this page to learn about the latest blood cancer research from the…
News Article
On December 29, 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or…
Videos
Multiple myeloma (MM) patients have an increased risk of severe coronavirus disease 2019 (COVID-19) when infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS) precedes MM and related disorders and affects 4.2…
Videos
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder preceding multiple myeloma and related disorders, present in 4.2% of the population over the age of 50. Although usually asymptomatic, MGUS has been associated with various health-related problems,…
Videos
Do patients with MGUS have a higher risk of contracting COVID-19 or experience more severe symptoms when infected?
In this episode, myeloma expert Dr. Brian G.M. Durie discusses if patients with MGUS are at higher risk of contracting COVID-19 or at an increased…
Videos
Although advances in the treatment of multiple myeloma (MM) have contributed to improved survival, treatment patterns and outcomes among patients with t(11;14) MM remain unknown. Chromosome translocation t(11;14) occurs in 15 – 20% of patients with MM and is regarded as a standard risk cytogenetic…
Videos
In addition to serum protein electrophoresis (SPEP) and serum immunofixation (IFE), measurement of serum free light chains (FLC) has become the hallmark for detection, prognostication, and monitoring of monoclonal gammopathies. However, serum FLC levels are heavily dependent on kidney function due…
Videos
Smoldering multiple myeloma (SMM) is an asymptomatic precursor condition to multiple myeloma (MM). Emerging data from clinical trials indicate that – compared to watchful monitoring – initiation of therapy at the SMM stage might be indicated. Currently, there is no established screening for SMM in…
News Article
Member organizations gather for a successful virtual meeting
By Serdar Erdoğan
IMF Director, GMAN and European & Middle Eastern Patient Programs
On December 15, 2021, representatives of the Global Myeloma Action Network® (GMAN®) member organizations…
Videos
Multiple myeloma (MM) evolves from monoclonal gammopathy of undetermined significance (MGUS), a clinically detectable but asymptomatic premalignant phase seen in ~3% of the general population 50 years of age or older. The prevalence of MGUS has not been described in a population at…
Event
In 2010 I was diagnosed with multiple myeloma. For the past five years I have participated in a Holiday Boutique selling handknit products to raise money for myeloma research.
Videos
Dr. Noemi Puig Discusses Findings From the GEM2012MENOS65 Clinical Trial Presented at the 2021 ASH Meeting.
In this video, Dr. Noemi Puig outlines how next generation flow cytometry (NGF) and next generation sequencing have shown an increased capacity to identify the presence of myeloma…
Videos
ASH 2021: Making Sense of Treatment
In this segment of the IMWG Conference Series, “Making Sense of Treatment,” leading myeloma experts discuss the latest drug therapy news from the annual American Society of Hematology (ASH) conference. Moderated by IMF Chairman of the Board Dr.…
Videos
How are the four iStopMM abstracts being presented at the 2021 ASH meeting relevant to myeloma patients?
In this episode, myeloma expert Dr. Brian G.M. Durie discusses the 4 iStopMM abstracts being presented at the ASH 2021 meeting.
The BOTTOM LINE: While these are early…
Event
Dr. Brian G.M. Durie discusses important takeaways relating to multiple myeloma from the annual American Society of Hematology (ASH) conference
Register now
Videos
M-Power Atlanta Community Workshop discusses:
Learn about multiple myeloma, a disease more than twice as common in people of African descent as in whites. From “Myeloma for Patients Who Are Just Getting Started” to the latest in…
News Article
Los Angeles, CA, November 12, 2021 –The International Myeloma Foundation (IMF) announced today that Yelak Biru, 51, a longtime myeloma patient advocate and former Data and Analytics Executive at PepsiCo and Walmart, has been named Chief Executive Officer of…
Videos
Have Questions About Myeloma? The IMF InfoLine Team Has Answers.
Find out how we are here for you.
Someone who's been diagnosed with myeloma has a million questions. The IMF’s InfoLine Team is here to answer your questions in a caring and compassionate manner. Learn more about how the IMF's…
Event
A virtual multiple myeloma workshop addressing the needs specific to communities in the state of Florida.
Page
The following videos, presented by Medscape Oncology, are designed for healthcare practitioners to earn certified medical education (CME) credits.
To earn these CME credits,
1. Register for free at…